Trial Profile
Safety and pharmacological evaluation of the intratumoral CIGB-300 application to patients with stage IB2-II cervical cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 14 Oct 2020
Price :
$35
*
At a glance
- Drugs CIGB 300 (Primary)
- Indications Cervical cancer
- Focus Pharmacokinetics
- Acronyms CERVIFARM-300
- 12 Dec 2013 Status changed from active, no longer recruiting to completed.
- 15 Feb 2013 New trial record